Bayer Misled Investors on Monsanto Deal Roundup Risk: Suit (1)

July 16, 2020, 5:32 PMUpdated: July 16, 2020, 9:16 PM

Bayer AG didn’t warn investors about the potential risk of billion-dollar judgments and reputation damage when it acquired Roundup maker Monsanto Co., a would-be class suit said in California federal district court.

The pharmaceutical and life sciences firm “specifically downplayed” liability risks related to Roundup weed killer, which some consumers have blamed for their non-Hodgkin lymphoma, two pension plans said Wednesday in their U.S. District Court for the Northern District of California complaint.

“We are confident that we have always acted in accordance with our obligations under the applicable securities laws,” Chris Loder, a spokesperson for Bayer’s U.S. operations, told ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.